QUANTRO Therapeutics has successfully completed its first 10-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for multiple molecular targets.  

After establishing its technology for single- and dual-target screenings at a current capacity of approximately one million compounds per year, QUANTRO has now completed the first simultaneous 10-target multiplexing high-throughput screening (HTS).  

This pilot project, which screened a 10,000-compound diversity library, met all quality control criteria and achieved a 100% hit rate for both positive and negative controls.  

Furthermore, QUANTRO’s platform identified hits across most of the selected targets, providing insights into transcriptional changes as well as on-target potency and selectivity, while minimising off-target effects. 

“This achievement represents a significant breakthrough for QUANTRO and more broadly for drug discovery, unlocking unprecedented opportunities for the discovery of novel targeted therapies,” said Dr Michael Bauer, CEO of QUANTRO. “By advancing our capabilities from single and dual target screenings now up to currently 10-target multiplexed high-throughput screenings, we are effectively profiling entire compound libraries for multiple targets, redefining the possibilities in transcription factor drug discovery.” 

QUANTRO was founded in 2019 as a spin-out from the research institutes IMBA and IMP in Vienna, Austria. Since 2020, the company has been supported by Boehringer Ingelheim Venture Fund (BIVF) and Evotec as seed investors.  

In total, €11 million was earned in milestone-driven tranches during 2020 and 2023, complemented by undisclosed proceeds from a strategic collaboration on selected oncology targets with Boehringer Ingelheim Oncology.

Diana Spencer, Senior Digital Content Editor, DDW